Gamma-Glutamyl Transpeptidase-to-Platelet Ratio Predicts Significant Liver Fibrosis of Chronic Hepatitis B Patients in China
Table 4
Diagnostic performances of serum models for liver fibrosis and cirrhosis.
Fibrosis (≥F1)
Significant fibrosis (≥F2)
Severe fibrosis (≥F3)
Cirrhosis (F4)
AUROC
(95% CI)
value
AUROC
(95% CI)
value
AUROC
(95% CI)
value
AUROC
(95% CI)
value
APRI
0.7
0.61–0.80
<0.001
0.63
0.54–0.72
0.006
0.64
0.55–0.74
0.006
0.63
0.52–0.78
0.043
GPR
0.77
0.68–0.86
<0.001
0.7
0.62–0.78
<0.001
0.71
0.62–0.79
<0.001
0.64
0.56–0.80
0.036
Fib-4
0.75
0.66–0.84
<0.001
0.7
0.62–0.79
<0.001
0.68
0.59–0.78
<0.001
0.67
0.52–0.81
0.009
Comparison of AUROC
GPR and APRI
0.03
0.02
0.02
0.25
GPR and Fib-4
0.14
0.22
0.13
0.24
APRI and Fib-4
0.06
0.01
0.07
0.23
APRI = aspartate transaminase-to-platelet ratio index; AUROC = the area under the receiver operating characteristic curve; CI = confidence interval; Fib-4 = fibrosis index based on the four factors; GPR = gamma-glutamyl transpeptidase-to-platelet ratio index.
